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The human C3b receptor (CR1) is a polymorphic gly-
coprotein comprised of a single polypeptide chain. Of 
the 4 allotype forms of CR1 that have been described, 
the 2 most common have Mr's of 250,000 and 260,000, 
and are regulated by alleles having frequencies in a 
Caucasian population of 81.5% and 18.5%, respectively. 
CRl is present on erythrocytes, neutrophils, eosinophils, 
monocytes, macrophages, B lymphocytes, some T lym-
phocytes, mast cells, and glomerular podocytes. CRl 
number on erythrocytes is genetically regulated, and 
ranges from less than 100 sites per cell to greater than 
1000 sites per cell, the average in the normal population 
being 500-600 sites per cell. A model accounting for 
this wide distribution proposes the existence of 2 codom-
inant alleles determining low and high receptor number 
respectively; CRl number is not affected by the struc-
tural polymorphism, so that the loci for these two phe-
notypic characteristics are distinct. The function of CRl 
on erythrocytes may be to promote the clearance of 
immune complexes from the circulation. CR1 number 
on myelomonocytic cells is regulated by chemotactic 
factors which can rapidly transfer CRl sites from a 
latent, presumably intracellular, site to the plasma mem-
brane of these cells, thereby enhancing their ability to 
interact with opsonized foreign material. The receptor 
is involved in the endocytic reactions of these cells, and 
recent findings have demonstrated that this function can 
be modulated by T cell-derived factors, fibronectin, and 
phorbol esters. The role of CRl on lymphocytes remains 
to be fully explored, although the receptor may enhance 
the differentiation of B cells into antibody-secreting 
cells. 
Several studies have documen ted a relative deficiency of CR1 
on erythrocytes in patients with systemic lupus erythematosus 
(SLE). In studies from Boston and Japan, the relatives of 
patients have been found also to have significantly fewer CR1 
sites on erythrocytes than did normal individuals, indicating 
that genetic factors had a role in the occurrence of the defi-
ciency. In 2 other reports, correlations of low receptor number 
with indices of disease activity have been found, suggesting 
that the deficiency may also be secondarily acquired in some 
individuals. 
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Abbreviations: 
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EBV: Epstein-Barr virus 
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PMA: phorbol myristate acetate 
SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis 
SLE: systemic lupus erythematosus 
The human C3d receptor (CR2) is a 145,000 M, protein that 
is present only on B lymphocytes. Although its normal role in 
the biology of the B cell is not known, studies employing the 
CR2-specific monoclonal antibodies, HB5 and anti-B2, CR2 
have shown it to be the receptor for the Epstein-Barr virus, a 
finding that explains the B cell tropism of this virus. 
The third component of complement, C3, is the most impor-
tant protein of the complement system. It is the most abundant 
of the complement components, being present in plasma at 
concentrations of 1-2 mg/ml; it is the point at which the 
classical and alternative pathways converge in the reaction 
sequences of the complement system; it is capable of forming a 
covalent linkage with the target of complement activation; and, 
derived from this protein are 5 cleavage fragments, C3a, C3b, 
iC3b, C3dg, and C3e, that can bind to 5 different receptors that 
reside on cells which participate in inflammatory and immu-
nologic reactions. In this summary recent findings concerning 
2 of these receptors, CR1 (also termed the C3b receptor) and 
CR2 (C3d receptor) will be described. 
STRUCTURAL CHARACTERISTICS OF CR1 (C3b 
RECEPTOR) 
CR1 reversibly binds C3b, iC3b and C4b, with the greatest 
affinity being for C3b. Multivalent interaction of ligand with 
this receptor is necessary for effective binding to occur [1], and 
most activators of complement, e.g., immune complexes and 
bacteria, covalently bind a multiplicity of C3b molecules. CR1 
has been purified to homogeneity from human erythrocytes 
and specific polyclonal antibody has been prepared [2,3). CR1 
is a large glycoprotein that exists in at least 4 allotypic forms 
differing by M" the most common forms having apparent M/s 
of 250,000 and 260,000 (4-7). Approximately two-thirds of a 
Caucasian population have only the lower M, form, one-third 
have both forms and 2.5 % have only the higher M, form [4). 
The CR1 allotypes do not differ in their affinity for C3b [ 4). 
Removal of N-Jinked oligosaccharides from purified CR1 by 
treatment with endoglycosidase F decreased by 10,000 the M, 
of both forms of CR1, as assessed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), but this treat-
ment did not abolish the difference in M, between the CR1 
allotypes [ 4). 
CR1 is present on human erythrocytes, neutrophils, eosino-
phils, monocytes, macrophages, B lymphocytes, a subpopula-
tion ofT lymphocytes, and glomerular podocytes. Analysis by 
SDS-PAGE of immunoprecipitates from erythrocytes, neutro-
phils monocytes, and B and T lymphocytes also has found no 
major differences in M, between CR1 of the different cell types 
[3], although the receptor from neutrophils [8) and T lympho-
cytes [9) appears to be slightly larger than that from the other 
cells. 
FUNCTIONS OF CR1 
Erythrocytes express an average of 500-600 CR1 per cell 
[1,3,10,11], and a wide range of 100- 1000 receptor sites per cell 
has been found among different normal individuals. Erythro-
cyte receptor number is a stable phenotypic characteristic. The 
depiction of erythrocyte CRl number of normal individuals in 
Boston as a frequency histogram reveals a bimodal distribution 
with 34% of the population having 600-1000 receptor sites per 
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cell and 54% having 350- 600 sites per cell. A third, less-distinct 
group has less t han 350 sites per cell and rep resents 12% of the 
normal populat ion. Two codom inant alleles have been proposed 
for regulation of the quantitative express ion of CR1 of eryth -
rocytes [10]. Persons having high numbers of CR1 (600- 1000 
per cell ) were considered to have the HH phenotype a nd to be 
homozygous for an allele determining high receptor number; 
individuals having fewer than 350 CR1 per cell , the LL phe-
notype, were homozygous for the low receptor allele; and those 
having intermediate numbers, 350- 600 sites per cell , were het-
erozygotes exhibi ting the HL phenotype . This hypothesis was 
supported by finding t he appropriate patterns of inheritance in 
7 families, including 1 normal family in which all 5 members 
had the relatively rare LL phenotype [10). No linkage was 
fou nd between the structural polymorphism of CR1 and its 
quantitative expression [4]. The finding of a tr imodal distri-
bution of this characteristic among normal individuals has been 
confirmed recently by a study from investigators in Japan 
indicating this to be an inheri ted trait t hat is not limited to a 
single population . 
CR1 on erythrocytes can serve at least 2 functions in the 
intravascular space where t hey are the major repository of this 
receptor. Fi rst, as on any cell type, it can se rve as a cofactor 
fo r t he factor !-mediated cleavage of C3b to iC3b (2,12,13) and 
C3dg [14). fragments that can bind to CR2 on B lymphocytes 
and CR3 on myelomonocytic cells. Second, the receptor endows 
erythrocytes with t he capacity for cycl ical uptake and release 
[15) of C3b- and iC3b-bearing immune complexes, an activity 
t hat may a llow erythrocytes to clear immune complexes from 
the circulation. In support of this are studies examining t he 
fate of model immune complexes in primates that demonstrated 
the delivery of erythrocyte-bound complexes to t he liver, via 
the portal circulation, where t he complexes were t ransferred to 
hepatic cells, presumably Kupfer cells [16]. 
Circulating neutrophils and monocytes express an average of 
only 5000 CR1 per cell but stimulation of these cells with 
chemotactic agents, such as C5a, formyl -methionyl-leucyl-
phenyl-alanine or leukotriene B., causes rapid up-regulation of 
recepto rs so that as many as 50,000 CR1 per cell become 
available for binding of ligand [17) . Increased CR1 expression 
on neutrophils also has been observed in vivo in patients who 
are experiencing complement act ivation secondary to hemodi -
alysis with dia lysis membranes that activate the alternative 
pathway [181. T he latent receptors are presumed to be intra-
cellular, but the prec ise site has not been identified. This 
mechanism for increasing the expression of CR1 could prepare 
chemotactically migrating cells for recognition of material that 
has been opsonized with C3b. 
T he primary function of CRl on neutrophils and monocytes 
is to mediate or enhance t he endocytosis of soluble complexes 
and particles to which C3b has bound covalently. Although 
internalization of soluble, multimeric ligand by CRl on t hese 
cells can occur through clathrin-coated pits and vesicles fol -
lowed by delivery to lysosomal structures [19,20). phagocytosis 
of particles by CR1 had generally been considered not to occur, 
most early studies having emphasized t he role of CRl in syn-
ergistically enhancing phagocytosis mediated by Fe receptors 
[21,22] . More recent ly, murine peritoneal macrophages that 
had been incubated with a supernatant of stimulated T cells 
were shown to have acquired a capacity for phagocytosis of 
sheep erythrocytes bea ring C3b [23]. A simila r change in the 
funct ional capacity of CR1 has been reported for human 
monocytes that had been cul tured for 1 week [24). stimulated 
with phorbol esters [25] or incubated with fibronectin (26,27], 
and fo r neutrophils exposed to phorbol esters (26) or with 
chemotactic peptides and fibronectin [28). A recent study has 
demo nstrated that phorbol myristate acetate (PMA) caused 2 
sequential changes in t he cellular distribution of CRl [29]. 
Incubation of neutrophils with PMA first led to the transloca-
tion of late nt CR1 to the plasma membrane and t his reaction 
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was followed within minutes by the interna lizat ion of t he CRl. 
Thus, presumptive activation of protein kinase C, a principal 
biological affect of PMA, induced the 2 reactions of CR1 
previously shown to occur with chemotactic peptides and mul-
tiva lent ligands, respectively. 
Analyses of the possible association of CRl with the cyto-
skeleton of neutrophils were stimulated by experiments meas-
uring the lateral mobility of CRl in t he plane of the plasma 
membrane of neutrophils. Whereas t here was relatively unre -
stricted mobility of CR1 on cells supported by a lipid monolayer 
[30). adherence of cells to quartz coverslips caused restricted 
movement of CR1 [31] . Recently, it has been shown that cross-
linking CRl on neut rophils at o·c with F(ab')2 ant ibody caused 
the receptor to become insoluble in nonionic detergents (32]. 
In addit ion, cross- linked receptors rapidly redistributed at 2o· c 
from punctate cluste rs into large patches and caps in a reaction 
that was accompanied by t he subplasmalemmal accumulation 
of acti n at t he site of caps [33]. This distribution of the receptor 
was inhibitable by cytochalasin D and chlorpromazine. In ap-
proximately half of the neutrophils which had capped t heir 
CR1, there was a corresponding redistribution of Fe receptors. 
The cocapping of CR1 and Fe receptors also occurred recipro-
cally so that unoccupied CR1 were found to redistribute with 
Fe receptors being capped with aggregated IgG [33]. Thus, 
there is a cytoskeletal-dependent cooperative interaction be-
tween CR1 and FeR on neutrophils induced by multivalent 
ligands that may augment t he phagocytosis by these cells of 
particles bearing both C3b and lgG. 
Essentially all mature human B lymphocytes from spleen or 
peripheral blood express CR1 [34). In comparison to unstimu-
lated neutrophils and monocytes, t he circulating B cell has 
available for binding of ligand a relatively la rge number of 
receptors, 20,000-40,000 CR1 per cell [17) . This number is not 
increased by chemotactic peptides, lipopolysaccharide or cul-
ture supernatants of mitogen-stimulated lymphocytes. CR1 
appears early in B cell ontogeny, being present on 15% of large 
pre-B cells, 35-50% of small pre-B cell s, and 60-80% of im-
mature cells [34], and is lost when B cells differe nt iate into 
plasma cells. The presence of CR1 on B cells had led to attempts 
to demonstrate a functiona l role for this membrane glycopro-
tein, but a clear definit ion is not available. Of great interest in 
this regard is the recent report that polyclonal rabbit F(ab 'h 
ant i-CR1 enhanced t he generation of ant ibody-secreting cells 
from peripheral blood mononuclear cells in response to subop-
timal doses of pokeweed mitogen [35]. Further studies ut ilizing 
natura l ligand, lymphocyte growth and differentiation factors 
and highly purified populat ions of B cells, T cells, and mono~ 
cytes should further define the role of CR1 in B cell differen-
tiation. 
The importance of employing highly purified subpopulations 
of lymphocytes in studying the role of CR1 in lymphocyte 
function is emphasized by the recent finding that in addition 
to B cells some T cells express CRl (9) . An average of 15% of 
peripheral blood lymphocytes forming rosettes with sheep 
erythrocytes were stained with fluoresceinated F(ab'h anti-
CR1 and t hese cells expressed approximately one-tenth t he 
amount of CR1 that was present on B cells. All sheep erythro-
cyte-rosetting, CR1-positive lymphocytes expressed t he T 3 an-
tigen, and the T4:T8 ratio among these cells was approximately 
4:1. Although greater than 90% of these cells bound aggregated 
IgG, suggesting the presence of Fe receptors for lgG, they had 
a typical lymphocyte morphology and were stained with HNK-
1, an antibody t hat recognizes large granular lymphocytes that 
bear Fe receptors. No functional studies of these CR1-bearina 
T cells have been performed. b 
STRUCTURE AND FUNCTION OF CR2 (C3d 
RECEPTOR) 
CR2 is present only on B lymphocytes and mediates t he 
binding of particles bearing the C3d fragment of C3. This 
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receptor a lso binds C3dg, iC3b and, more weakly, C3b in which 
the C3d region may be only partially exposed. Two studies 
employing 2 monoclonal antibodies have identified the mem-
brane protein serving as CR2 [36- 39]. 
In the first study (36], the monoclonal antibody termed anti-
B2 (38] inhibited the formation of rosettes between B cells and 
Raji cells with sheep erythrocytes bearing C3d or iC3b. A B-
cell membrane protein of 140,000 M, bound to Sepharose to 
which anti-B2 or C3d had been coupled, and the isoelectric 
points of the 140,000 M, membrane protein binding to Sephar-
ose-C3 and to Sepharose-anti-B2 were shown to be identical. 
The second study [37] employed a monoclonal antibody termed 
HB-5 (39] which a lso recognized a B cell -specific membrane 
protein of 145,000 M,. HB-5, when combined with a second 
antibody, was found to inhibit the formation of rosettes be-
tween Raji ce lls with sheep erythrocytes bearing C3d, iC3b, or 
C3b. A direct ana lysis of the ligand binding activity of the HB-
5 antigen was performed by priming Staphylococcus aureus 
particles with the HB-5 antibody and reacting the particles 
with detergent lysates of Raji cells or B cells under conditions 
that led to the uptake only of the HB-5 antigen . The S. aureus 
particles bearing HB-5 antigen-antibody complexes were found 
to bind to sheep erythrocytes coated with C3d, iC3b, or C3b; 
binding of the particles to erythrocytes coated with C3b was 
relatively weak as had been observed for the rosette reaction of 
Raji cells with these erythrocytes. Thus, transferring the HB-
5 antigen from Raji cells to S. aureus conferred on t he latter a 
complement receptor fu nction t hat was identical to that of the 
former. It has been forma lly demonstrated that B2 and the 
HB-5 antigen bind to different epitopes on the same protein. 
The normal biologic functions of CR2 are not known. 
However, this receptor has recently been shown to be the 
receptor for the Epstein-Barr virus (EBV) (40]. The possibility 
t hat the human B-cell surface receptor for Epstein-Barr virus 
(EBVR), a human herpes vi rus associated with infectious 
mononucleosis, Burkitt's lymphoma, and nasopharyngeal car-
cinoma, is related to receptors for the third component of 
complement (C3) has been recognized for several years 
(41,42]. The EBVR and C3 receptors were coincidentally ex-
pressed (41- 43] and induced (44] on B-celllines and on periph-
eral blood B lymphocytes. They cocapped (45] and were mu-
tually depleted after membrane stripping [ 46]. Uptake of virus 
by lymphoblastoid ce lls interfered with the binding of sheep 
erythrocytes coated with C3 fragments [ 41 ] and sequential 
treatment with human C3, rabbit anti-C3 antibody, and goat 
antirabbit lg blocked adherence of EBV (41]. Identity of the 
EBV receptor with the complement receptor type 2 (CR2) was 
established in 3 sets of experiments using the 2 monoclonal 
antibodies, HB-5 and anti-B2, that recognize the 145,000 M, 
B-lymphocyte membrane protein that is CR2. First, the rank 
order for binding of fluoresceinated EBV to 4 lymphoblastoid 
cell lines (SB, JY, Raji, and Molt-4) was identical to the rank 
order for binding of HB-5 and anti -B2 by analytical flow 
cytometry. Second, pretreatment of cells with HB-5 followed 
by treatment with goat F(ab')z fragments to mouse lgG blocked 
binding of tluoresceinated EBV on SB, a B-lymphoblastoid cell 
line. Virus attachment was not inhibited by HB-5 alone, second 
antibody alone, rabbit anti-C3b receptor, or UPClO (an irrele-
vant monoclonal antibody). Third, transfer of CR2 from SB to 
protein A-bearingS. aureus particles, to which HB-5 had been 
absorbed, conferred on t hem t he specific ability to bind 1251-
labeled EBV. Thus, it was concluded that CR2 was the EBV 
receptor of human B lymphocytes, explaining the B-cell trop-
ism of EBV. These studies may also provide insight into the 
normal function of CR2, as EBV induces proliferation and 
maturation of B cells into antibody-secreting cells. 
ABNORMALITIES OF CR1 IN SLE 
Six studies have reported that erythrocytes from some SLE 
patients are relatively deficient in CR1, indicating that the 
abnormality is geographically widespread and reproducibly de-
monstrable among various investigative groups [10,11,47-50]. 
Both functiona l (10,11,47,49] and antigenic assays of CR1 
[10,1 1,48,50] have been employed with similar results, the mean 
number among patients being consistently 40-60% that of 
normals. In one study the number of binding sites for dimeric 
C3b and for anti-CRl on erythrocytes from normals and pa-
tients was shown to correlate (p < 0.005), and the affinity for 
dimeric C3b of CR1 on cells from patients and normals did not 
differ (10]. The frequency of t he two major polymorphic forms 
of CR1 was the same among SLE patients and normal persons 
(6], regardless of CR1 number on erythrocytes [4], except for a 
possible increased occurrence of a rare variant of 160,000 M, in 
the patient population [6] . In summary, most patients appeared 
to have low numbers of normal CR1 on their erythrocytes 
rather than nonfunctional, structurally altered forms of the 
protein that were antigenically intact. 
Two general mechanisms have been proposed to account for 
the receptor deficiency in SLE: one postulates that it is inher-
ited [ 10,11,4 7] and the other that it is acquired as a consequence 
of pathologic processes associated with the disease [48,50]. 
Although having evidence for the occurrence of either process 
does not exclude the other, establishing the validity of the 
former is most critical as this would define a genetically regu-
lated trait that, in combination with other inherited and envi-
ronmental factors, predisposes to the occurrence of SLE. The 
first study describing the CR1 deficiency in Japanese SLE 
patients noted that 6 of 24 relatives of patients also had the 
abnormality, compared to 4 out of 104 normal subjects [47]. In 
a second study performed in Boston, erythrocytes from 4 7 
relatives of 6 probands were assessed [10]. Cells from the 
patients had an average CR1 number that was 41 % of the 
normal mean, and the mean CR1 number of the relatives' cells 
was 63% of normal, both measurements being significantly 
lower than the normal population. Spouses of 14 patients did 
not differ from the normal population in this measurement , 
suggesting that the low number of CR1 among the consangui-
neous relatives was not acquired through physical contact with 
patients. This study has now been confirmed by the Japanese 
investigators who not only found a trimodal distribution of 
CR1 number on erythrocytes in the normal population, con-
sistent with inheritance of this trait among normals, but a lso 
described familial transmission in SLE patients (10]. Sixteen 
relatives of 5 probands, whose cells averaged 39% of the normal 
CR1 number, had erythrocytes expressing an average of only 
64% of the normal mean CRl number. Thus, in 2 distinct 
populations, Japanese and North American, inheritance has a 
major role in the CRl deficiency in SLE patients. 
A recent study involving patients from Great Britain and 
North Carolina presented findings that emphasized the role of 
disease processes in the acquisition of low CRl number on 
erythrocytes in SLE [50]. Although a significant correlation 
was fou nd between erythrocyte CRl of parents and children in 
normal fam ilies, supporting the model of codominant inherit-
ance, no such correlation was observed in SLE families. Instead, 
increased amounts of C3dg were found on erythrocytes of SLE 
patients, and the numbers of C3dg molecules correlated in-
versely with the number of CRl molecules per cell. These 
findings were interpreted as indicating that complement acti-
vation may occur on erythrocytes of SLE patients, perhaps by 
receptor-bound immune complexes, and that this process 
caused the loss or degradation of CRl sites by an unknown 
mechanism. In support of this conclusion were the findings of 
low CRl also in patients with autoimmune hemolytic anemia, 
and in patients with circulating immune complexes associated 
with infectious diseases. An earlier report [ 48] that did not 
perform family studies demonstrated that erythrocyte CRl 
number among patients varied inversely with serum immune 
complex levels and directly with C4 levels, and that CRl sites 
increased in 2 of 4 patients during remission of disease activity. 
56s FEARON 
T hus, t here is good evidence to ind icate that pathologic proc-
esses also may secondarily dimin ish the expression of CRl by 
erythrocytes in SLE patients and obscure t he detection of 
genetic regu lation of CRl number which, in this study, was 
apparent only amo ng normal persons. 
Add it ional studies must be carried out to examine carefully 
both the molecular biologic mechanisms t hat determine the 
number of CRl on erythrocytes and the pathologic processes 
involved in secondary diminut ion of erythrocyte CRl. Furt her, 
t he nucleated cells t hat express CRl should be assessed in SLE 
patients fo r possible abnormalit ies involving t his and t he other 
C3 receptors. Studies have a lready demonstrated the absence 
of CRl on glomerular podocytes of patients wit h prolife rative 
nephrit is of SLE, which contrasted with the apparently normal 
expression of CRl by t hese ce lls in membranous lupus nephrit is 
and in other types of endocapillary proli ferat ive nephrit is 
[51,52 ]. Finally, t he demonstration of diminished CR l on eryth-
rocytes of patients with other diseases, such as juvenile [53] 
and adul t rheumatoid arthri t is [ 48,49], leukemia [ 49], autoim-
mune hemolytic anemia [50], and leprosy [54], and of decreased 
CRl function on reticuloendothelial cells of patients wit h SLE 
r55] and prima ry bilia ry cirrhosis [56] must attempt to discrim-
mate between inherited and acquired abnormalit ies wit h the 
realization that both processes may occur. 
Possible mechan isms by which inherited abnormali t ies of the 
CRl might predispose to immunologically- mediated disease 
have been discussed elsewhere [57], and include impaired clear-
ance and processing of immune complexes. Indeed, even before 
patients with SLE were recognized to have a relative defi ciency 
of erythrocyte CRl , an association between auto immune dis-
ease and inher ited ab normalit ies of prote ins of the classical 
pathway of complement, Clq, Cl r, Cls, C4, C2, and C3, had 
been appreciated [58]. Because Cl, C4, C2, and C3 are t he 
components that are invo lved in the deposit ion on ant igen-
ant Jody complexes of C3b, t he li gand for CRl , it may be t hat 
the occurre nce of SLE in t hese and the CRl-deficient individ-
uals involve similar mechanisms. 
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